HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases DOI Creative Commons
Geetha Shanmugam, Sudeshna Rakshit, Koustav Sarkar

et al.

Translational Oncology, Journal Year: 2021, Volume and Issue: 16, P. 101312 - 101312

Published: Dec. 16, 2021

Histone deacetylases (HDACs) are enzymes that play a key role in the epigenetic regulation of gene expression by remodeling chromatin. Inhibition HDACs is prospective therapeutic approach for reversing alteration several diseases. In preclinical research, numerous types HDAC inhibitors were discovered to exhibit powerful and selective anticancer properties. However, such research has revealed effects may be far broader more intricate than previously thought. This review will provide insight into their mechanism action with special emphasis on significance treatment Chronic Obstructive Pulmonary Disease lung cancer. Nanocarrier-mediated inhibitor delivery new approaches targeting also discussed.

Language: Английский

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives DOI Creative Commons
Lei Zhong, Yueshan Li, Liang Xiong

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: May 31, 2021

Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since first tyrosine kinase inhibitor imatinib was approved enter market by US Food Drug Administration (FDA) 2001, an increasing number of small-molecule been developed for treatment malignancies. By December 2020, 89 antitumor FDA National Medical Products (NMPA) China. Despite great progress, anti-cancer still face many challenges, such as a low response rate drug resistance. To better promote development we conducted comprehensive review according target classification. We present all well important candidates clinical trials each target, discuss current provide insights perspectives research drugs.

Language: Английский

Citations

1198
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi DOI Creative Commons
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard

et al.

Frontiers in Oncology, Journal Year: 2018, Volume and Issue: 8

Published: March 29, 2018

Genetic and epigenetic changes in DNA are involved cancer development tumor progression. Histone deacetylases (HDACs) key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones. HDACs dysregulated many cancers, making them a therapeutic target for the treatment cancer. HDAC inhibitors (HDACi), novel class small-molecular therapeutics, now approved Food Drug Administration anticancer agents. While they have shown great promise, resistance to HDACi is often observed furthermore, limited success treating solid tumors. The combination with standard chemotherapeutic drugs has demonstrated promising effects both preclinical clinical studies. In this review, we summarize research thus far on therapy, other anti-cancer agents their translation into We additionally highlight side associated therapy discuss potential biomarkers either select or predict patient's response these agents, order limit off-target toxicity HDACi.

Language: Английский

Citations

593
Epigenetic modifications of histones in cancer DOI Creative Commons
Zibo Zhao, Ali Shilatifard

Genome biology, Journal Year: 2019, Volume and Issue: 20(1)

Published: Nov. 20, 2019

Abstract The epigenetic modifications of histones are versatile marks that intimately connected to development and disease pathogenesis including human cancers. In this review, we will discuss the many different types histone biological processes with which they involved. Specifically, review enzymatic machineries involved in cancer progression, how apply currently available small molecule inhibitors for modifiers as tool compounds study functional significance their clinical implications.

Language: Английский

Citations

455
Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases DOI Creative Commons

Rachel Fellows,

Jérémy Denizot, Claudia Stellato

et al.

Nature Communications, Journal Year: 2018, Volume and Issue: 9(1)

Published: Jan. 3, 2018

Abstract The recently discovered histone post-translational modification crotonylation connects cellular metabolism to gene regulation. Its regulation and tissue-specific functions are poorly understood. We characterize in intestinal epithelia find that H3 at lysine 18 is a surprisingly abundant the small intestine crypt colon, linked show this highly dynamic regulated during cell cycle. identify class I deacetylases, HDAC1, HDAC2, HDAC3, as major executors of decrotonylation. known HDAC inhibitors, including gut microbiota-derived butyrate, affect Consistent with this, we depletion microbiota leads global change colon. Our results suggest chromatin microbiota, least part, via short-chain fatty acids HDACs.

Language: Английский

Citations

438
Aging and age‐related diseases: from mechanisms to therapeutic strategies DOI Open Access
Zhe Li, Zhenkun Zhang,

Yikun Ren

et al.

Biogerontology, Journal Year: 2021, Volume and Issue: 22(2), P. 165 - 187

Published: Jan. 27, 2021

Language: Английский

Citations

438
Ketogenic diet in the treatment of cancer – Where do we stand? DOI Creative Commons
Daniela D. Weber, Sepideh Aminzadeh-Gohari,

Julia Tulipan

et al.

Molecular Metabolism, Journal Year: 2019, Volume and Issue: 33, P. 102 - 121

Published: July 27, 2019

Cancer is one of the greatest public health challenges worldwide, and we still lack complementary approaches to significantly enhance efficacy standard anticancer therapies. The ketogenic diet, a high-fat, low-carbohydrate diet with adequate amounts protein, appears sensitize most cancers treatment by exploiting reprogramed metabolism cancer cells, making promising candidate as an adjuvant therapy.To critically evaluate available preclinical clinical evidence regarding in context therapy. Furthermore, highlight important mechanisms that could explain potential antitumor effects diet.The probably creates unfavorable metabolic environment for cells thus can be regarded patient-specific multifactorial majority several studies argue use combination therapies based on its classic chemo- radiotherapy, overall good safety tolerability increase quality life. However, further elucidate therapy application practice, more molecular well uniformly controlled trials are needed.

Language: Английский

Citations

381
Metabolism of Amino Acids in Cancer DOI Creative Commons
Zhen Wei, Xiaoyi Liu, Chunming Cheng

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2021, Volume and Issue: 8

Published: Jan. 12, 2021

Metabolic reprogramming has been widely recognized as a hallmark of malignancy. The uptake and metabolism amino acids are aberrantly upregulated in many cancers that display addiction to particular acids. Amino facilitate the survival proliferation cancer cells under genotoxic, oxidative, nutritional stress. Thus, targeting acid is becoming potential therapeutic strategy for patients. In this review, we will systematically summarize recent progress malignancy discuss their interconnection with mammalian target rapamycin complex 1 (mTORC1) signaling, epigenetic modification, tumor growth immunity, ferroptosis. Finally, highlight applications.

Language: Английский

Citations

309
The language of chromatin modification in human cancers DOI
Shuai Zhao, C. David Allis, Gang Greg Wang

et al.

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(7), P. 413 - 430

Published: May 17, 2021

Language: Английский

Citations

302
Oral squamous cell carcinomas: state of the field and emerging directions DOI Creative Commons

Yunhan Tan,

Zhihan Wang,

Mengtong Xu

et al.

International Journal of Oral Science, Journal Year: 2023, Volume and Issue: 15(1)

Published: Sept. 22, 2023

Oral squamous cell carcinoma (OSCC) develops on the mucosal epithelium of oral cavity. It accounts for approximately 90% malignancies and impairs appearance, pronunciation, swallowing, flavor perception. In 2020, 377,713 OSCC cases were reported globally. According to Global Cancer Observatory (GCO), incidence will rise by 40% 2040, accompanied a growth in mortality. Persistent exposure various risk factors, including tobacco, alcohol, betel quid (BQ), human papillomavirus (HPV), lead development potentially malignant disorders (OPMDs), which are lesions with an increased developing into OSCC. Complex multifactorial, oncogenesis process involves genetic alteration, epigenetic modification, dysregulated tumor microenvironment. Although therapeutic interventions, such as chemotherapy, radiation, immunotherapy, nanomedicine, have been proposed prevent or treat OPMDs, understanding mechanism facilitate identification prognostic thereby improving efficacy treatment patients. This review summarizes mechanisms involved Moreover, current interventions methods OPMDs discussed comprehension provide several prospective outlooks fields.

Language: Английский

Citations

294
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability DOI Open Access
Giorgio Milazzo, Daniele Mercatelli, Giulia Di Muzio

et al.

Genes, Journal Year: 2020, Volume and Issue: 11(5), P. 556 - 556

Published: May 15, 2020

Histone deacetylases (HDACs) are evolutionary conserved enzymes which operate by removing acetyl groups from histones and other protein regulatory factors, with functional consequences on chromatin remodeling gene expression profiles. We provide here a review the recent knowledge accrued zinc-dependent HDAC family across different species, tissues, human pathologies, specifically focusing role of inhibitors as anti-cancer agents. will investigate chemical specificity HDACs discuss their in interactome members chromatin-binding complexes.

Language: Английский

Citations

275